Rinvoq vs Simponi

Listen to the article instead of reading through it.

0:00

Introduction

For patients with rheumatoid arthritis (RA) or other types of inflammatory autoimmune disorders, certain drugs that block the action of specific proteins in the body, called cytokines, can help in reducing inflammation and managing symptoms. Rinvoq and Simponi are two such drugs that are commonly prescribed for these conditions. They each target different signaling pathways, but both have anti-inflammatory effects in patients with RA or similar diseases. Rinvoq is a Janus kinase inhibitor (JAK), affecting levels of various cytokines and growth factors involved in immune response and hematopoiesis by inhibiting their transmission signals. Simponi on the other hand, is classified as a tumor necrosis factor (TNF) blocker acting primarily to neutralize TNF-alpha, a protein causing inflammation when overproduced in the body.

What is Rinvoq?

Upadacitinib (the generic name for Rinvoq) was developed as a part of the JAK inhibitors class of drugs, which marked a considerable breakthrough from the first class of biologics known as tumor necrosis factor (TNF) inhibitors. Upadacitinib received FDA approval in 2019. Rinvoq works by inhibiting particular enzymes called Janus kinases that aid in mediating the body's immune response, thereby reducing inflammation and other symptoms associated with autoimmune disorders such as rheumatoid arthritis or ulcerative colitis. On the other hand, Golimumab (Simponi), an older medication approved by FDA in 2009, is a TNF inhibitor that blocks the inflammatory protein TNF-alpha to reduce inflammation and pain associated with various autoimmune conditions. While both medications are effective at treating these conditions, Rinvoq's selective inhibition on specific types of Janus kinases results in it having fewer side effects compared to Simponi which has broader immunosuppressive effects.

What conditions is Rinvoq approved to treat?

Rinvoq is approved for the treatment of several autoimmune conditions, including:

Moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate
Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs)
Active ankylosing spondylitis in adults

Simponi, on the other hand, is used for:

Rheumatoid Arthritis (with methotrexate),
Psoriatic Arthritis,
Ankylosing Spondylitis and
Ulcerative Colitis.

How does Rinvoq help with these illnesses?

Rinvoq aids in managing rheumatoid arthritis by inhibiting the function of certain proteins known as Janus kinases. These enzymes play a key role in triggering an immune response, which can lead to inflammation and joint damage when overly active. Rinvoq curbs this process by blocking these enzymes, keeping levels moderated for longer periods of time. This helps to minimize inflammation and pain associated with conditions like rheumatoid arthritis.

Simponi works similarly but acts at a different point in the inflammatory pathway. It targets tumor necrosis factor-alpha (TNFα), a cytokine that is overproduced in patients with autoimmune conditions such as rheumatoid arthritis, leading to excessive inflammation and tissue damage. By neutralizing TNFα, Simponi effectively dampens down the inflammatory response.

Both drugs serve similar purposes—namely reducing symptoms related to autoimmune diseases—but they act on different parts of the body's immune system machinery.

What is Simponi?

Simponi (generic name golimumab) is a tumor necrosis factor (TNF) inhibitor, meaning it obstructs the action of TNF, a substance in the body that can cause inflammation and related symptoms. It was first approved by the FDA in 2009. Golimumab does not inhibit interleukin molecules directly unlike Rinvoq which inhibits Janus Kinase enzymes involved in inflammatory responses. This difference defines Simponi’s unique mode of action. Its targeted approach on TNF means that its side-effect profile may differ from drugs like Rinvoq—in particular, it's less likely to cause issues such as nausea or upper respiratory tract infections (common side effects associated with JAK inhibitors). The effects on TNF can be beneficial for the treatment of autoimmune conditions like rheumatoid arthritis and psoriatic arthritis, especially in patients who do not respond well to “typical” DMARDs or other biologic therapies.

What conditions is Simponi approved to treat?

Simponi is a medication that has been approved by the FDA for the treatment of:

Rheumatoid arthritis (RA), which can cause pain, swelling, and loss of joint function
Psoriatic arthritis (PsA), a condition characterized by skin disease and joint inflammation
Ankylosing spondylitis (AS), a type of inflammatory arthritis affecting primarily the spine
Ulcerative colitis (UC), an inflammatory bowel disease causing long-lasting inflammation and ulcers in your digestive tract.

How does Simponi help with these illnesses?

Tumor necrosis factor (TNF) is a cytokine involved in systemic inflammation and has been implicated in the pathophysiology of autoimmune diseases like rheumatoid arthritis. Simponi functions by selectively inhibiting TNF, leading to reduced inflammation and thus helping manage symptoms such as joint pain and swelling. Its specific action on TNF positions it effectively for combating inflammatory conditions. Although Rinvoq also treats rheumatoid arthritis, its mechanism differs - it interferes with immune cell signaling pathways that contribute to inflammation. While both medications are effective options, Simponi might be chosen over Rinvoq if you've previously responded well to anti-TNF drugs or when other treatments have not worked sufficiently.

How effective are both Rinvoq and Simponi?

Both upadacitinib (Rinvoq) and golimumab (Simponi) have demonstrated efficacy in treating patients with rheumatoid arthritis, despite being approved by the FDA nearly a decade apart. The two drugs operate on different pathways of inflammation, hence may be prescribed under varying circumstances based on patient needs. Rinvoq's effectiveness was studied extensively in several double-blind clinical trials where it showed positive results in mitigating symptoms of rheumatoid arthritis and also exhibited a promising safety profile.

A review conducted in 2019 reports that Rinvoq is effective at alleviating symptoms within the first couple of weeks of treatment. Aside from reducing pain and stiffness associated with rheumatoid arthritis, this medication has also been found to lessen fatigue experienced by patients. Despite its relatively recent approval compared to other drugs for this condition, many studies support its use as an alternative when conventional treatments are not working efficiently or don't suit the patient due to side effects.

On the other hand, Simponi has proven more successful than placebo treatments for managing symptoms of rheumatoid arthritis according to several meta-analyses carried out since its approval in 2009. While it is generally considered only after traditional DMARDs (Disease-modifying antirheumatic drugs), significant research supports its use either alone or alongside methotrexate - another common drug used for treating RA. However, like all medications designed for long-term management of chronic conditions such as RA, both these drugs carry certain risks that need consideration before prescribing them – including potential adverse reactions and interactions with other medicines.

abstract image of a researcher studying a bottle of drug.

At what dose is Rinvoq typically prescribed?

The standard dosage of Rinvoq for adults with rheumatoid arthritis is 15 mg taken orally once a day. It's important to note that Rinvoq isn't recommended for use in children. On the other hand, Simponi is an injectable medication typically administered as a 50 mg subcutaneous injection once a month for adults suffering from conditions like rheumatoid arthritis or ulcerative colitis. Similar to Rinvoq, Simponi is not generally prescribed to children or adolescents. Dosages may be adjusted based on patient response and tolerance, but under no circumstances should these standard dosages be exceeded without consulting healthcare professionals.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is Simponi typically prescribed?

Simponi treatment is typically initiated with a subcutaneous injection of 50 mg once per month. For patients with rheumatoid arthritis, it can be used in combination with methotrexate. For the treatment of psoriatic arthritis or ankylosing spondylitis, Simponi can be administered as monotherapy if necessary. If there is no response to treatment after several weeks, your healthcare provider may want to reassess and consider alternative treatments. It's essential that doses are spaced at least four weeks apart for maximum efficacy without compromising safety.

What are the most common side effects for Rinvoq?

Common side effects of Rinvoq can include:

Upper respiratory tract infections
Nausea
Fatigue (general weakness and tiredness)
Cough
Fever
Rash

On the other hand, common side effects of Simponi may include:

Upper respiratory tract infection
Reaction at injection site (redness, itching, pain)
Diarrhea
Sinusitis (inflammation in sinus cavities)

These are not exhaustive lists. If you experience these or any other troubling symptoms after starting medication, consult your healthcare provider immediately.

abstract image of a patient experiencing side effect

Are there any potential serious side effects for Rinvoq?

While both Rinvoq and Simponi are effective treatments for autoimmune diseases, they can cause serious side effects in some cases. Potential adverse reactions include:

Signs of severe allergic reaction: hives, difficulty breathing, swelling of your face or throat
Symptoms suggestive of infections such as fever, sweats or chills, muscle aches, coughs that don't go away or skin sores
Changes in vision including blurred vision or other issues with eyesight
Heartbeat irregularities - rapid heartbeats or palpitations which may be accompanied by feeling light-headed
Symptoms related to low levels of sodium like confusion, headache, slurred speech and instability while standing up
Neurological problems - rigidity of muscles coupled with high fever and sweating leading to tremors and fainting spells.

Additionally for Rinvoq:

Any symptoms suggesting blood clot formation like chest pain spreading to arms/jaw/neck/back along with shortness of breath.

For Simponi:

Signs indicative of Hepatitis B reactivation (for those who had it before) which includes feeling unwell overall along with loss of appetite followed by yellowing skin/eyes.

If you experience any unusual discomfort after starting these medications consult your doctor immediately.

What are the most common side effects for Simponi?

When taking Simponi, you may experience:

Upper respiratory tract infection such as a stuffy or runny nose and sore throat
Headache and dizziness
Rash or skin reactions at the injection site
Increased blood pressure
Nausea, abdominal pain, constipation or diarrhea
Liver enzyme elevations which could indicate liver damage
Allergic reactions like hives, difficulty breathing, swelling of your face, lips, tongue or throat. Remember that any medication can cause side effects. However not everyone experiences them. Always discuss potential risks and benefits with your healthcare provider before initiating any new treatment.

Are there any potential serious side effects for Simponi?

While Simponi is generally well-tolerated, it can produce some potentially serious side effects. These include:

Signs of an allergic reaction or severe skin reaction: hives, itching, fever, swollen glands; difficulty breathing; swelling in your face or throat; sore throat; burning eyes; skin pain and a red or purple skin rash with blistering and peeling.
Hepatitis B reactivation in carriers of the virus: symptoms could include feeling unwell, poor appetite, tiredness, fever followed by nausea/vomiting/abdominal pain/joint pain/dark urine.
New onset psoriasis - including pustular and palmoplantar types.
Heart failure — shortness of breath (especially when lying down), fatigue and weakness especially during increased physical activity, swelling in your legs, ankles and feet.

If you experience any of these symptoms while taking Simponi immediately contact your healthcare provider.

Contraindications for Rinvoq and Simponi?

Both Rinvoq and Simponi, along with most other medications used for the treatment of rheumatoid arthritis, may worsen symptoms in some people. If you notice your condition worsening or an increase in unusual weakness, fatigue, or fevers please seek immediate medical attention.

Neither Rinvoq nor Simponi can be taken if you are taking or have recently been taking any type of biological therapy for rheumatoid arthritis (like Rituximab). Always inform your doctor about the current medications you're using; biological therapies will require a period of around 5 months to clear from the system to prevent dangerous interactions with Rinvoq and Simponi.

How much do Rinvoq and Simponi cost?

For the brand name versions of these drugs:

The price of a 30-day supply (15mg) of Rinvoq averages around $5,900, which works out to about $197/day.
The price for one pre-filled syringe (50 mg) of Simponi is approximately $4,400. As it's typically administered once a month, this equates to roughly $147/day.

Thus, on a per-day treatment basis, Simponi may be less expensive than Rinvoq. However please note that cost should not be the sole consideration in determining which drug is right for you; efficacy and side effects are significant factors as well.

It's important to mention there are currently no generic alternatives available for either Rinvoq or Simponi due to patent protections. Therefore these costs represent the baseline pricing without insurance coverage or discount programs.

Popularity of Rinvoq and Simponi

Upadacitinib, sold under the brand name Rinvoq, was approved by the FDA in 2019 for treating moderate to severe rheumatoid arthritis. Because it’s relatively new on the market compared to other drugs used for this condition, specific prescription numbers aren't readily available; however, its novel mechanism of action and promising efficacy have increased interest among healthcare providers.

Golimumab is an older medication marketed as Simponi that has been available since 2009. It's used not only for rheumatoid arthritis but also psoriatic arthritis and ankylosing spondylitis. In 2020 alone, more than a million prescriptions were written out for Simponi in the US indicating its widespread acceptance and use over time.

While both medications are classified as disease-modifying antirheumatic drugs (DMARDs), they function differently at a molecular level: Rinvoq is a JAK inhibitor while Simponi is a TNF-alpha blocker. The choice between them would depend on individual patient factors including disease severity, co-existing conditions and tolerance or response to previous treatments.

Conclusion

Both Rinvoq (upadacitinib) and Simponi (golimumab) are proven to be effective in treating patients with rheumatoid arthritis, backed by numerous clinical studies and meta-analyses indicating their effectiveness over placebos. In some instances, these drugs may be used together but this should only occur under the careful supervision of a physician due to potential interactions between them. Their mechanisms of action differ, with Rinvoq inhibiting Janus kinases which play an important role in inflammation while Simponi blocks tumor necrosis factor-alpha implicated in inflammatory processes.

Rinvoq is generally chosen as a treatment option when conventional disease-modifying antirheumatic drugs (DMARDs) have failed or shown limited efficacy. On the other hand, Simponi is often utilized as additional therapy to methotrexate or can be prescribed alone, depending on individual patient responses.

Neither drug has generic options currently available which unfortunately does not offer cost savings for patients who must pay out-of-pocket. Both medications require an adjustment period meaning that effects may not become apparent immediately after starting treatment.

The side effect profiles of both Rinvoq and Simponi share similarities like increased risk of infections due to immune system suppression but they also possess unique risks; Rinvoq has been linked to blood clots whilst Simponi might increase cancer risk among long-term users. Patients need vigilant self-monitoring especially when initiating treatment and should seek immediate medical attention if adverse symptoms manifest or existing ones worsen.